David Brizel is an Oncology physician affiliated with Duke University. OpenAlex indexes 266 publications with 18,780 citations (h-index 65); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Radiation Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4101 N Roxboro St
Durham, NC 277042121
Telephone
919-684-8111Provider last certified this registry record 27 Jun 2023.
Clinical trials
- Functional Imaging of Tumor and Normal Tissue
Sponsor: Duke University
- Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Sponsor: Jazz Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202211 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
61.1%Antiarrhythmic61.1%Lidocaine Hcl Viscous100%Part D≥12 patientsNervous system
38.9%Opioid Agonist38.9%Oxycodone Hcl100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2000–2020 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Journal of the National Comprehensive Cancer Network
2025 - NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Journal of the National Comprehensive Cancer Network
2022 - Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”